Colchicine treatment can be discontinued in a selected group of pediatric FMF patients

• DOI: 10.1186/s12969-022-00780-w
• Publication Date: 2023-01-04T08:05:54Z
• Authors: Keren Cohen; Shiri Spielman; Rotem Semo-Oz; Guy Bitansky; Maya Gerstein; Yonatan Yacobi; Asaf Vivante; Irit Tirosh
• Keywords: Colchicine

Familial Mediterranean Fever (FMF) patients are required to adhere a life-long treatment with colchicine, primarily for preventing amyloidosis. As some may be asymptomatic long periods of time, it remains unclear whether is possible discontinue colchicine in selective group patients. We aimed identify predictive characteristics successful cessation therapy.Out 646 FMF pediatric followed our referral clinic, was discontinued 51 In this study we compared the genetic, demographic, and clinical between whom therapy made (Group 1; n = 21) deemed failure 2; 30) consequently had resume therapy.Patients achieved no biallelic pathogenic MEFV mutations, were less likely have "severe attacks" (two or more characteristic symptoms) (24% vs 80%; P 0.000067) did not require higher than 1 mg/day prior drug cessation. Remission duration under significantly 2 (4.36 years ±2.12 2.53 ±2; 0.0036).This supports concept free remission minority (3%). Holding treatment, close monitoring, reasonable when selecting appropriate